23rd ASGCT: Cell Therapy NTLA-5001 for the treatment of acute myeloid leukemia!
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Intelli Therapeuticas, a leading genome editing company dedicated to developing therapeutic drugs using CRISPR/Cas9 technology, will present a report at the 23rd annual meeting of the American Society for Gene and Cell Therapy (ASGCT) detailing the effectiveness and safety of cell therapy NTLA-5001 for the treatment of acute myeloid leukemia (AML)Intellia also mentioned the cell therapy NTLA-2002, which is expected to be used to treat hereditary angioedema (HAE)DrJohn Leonard, President and CEO of Intellia, said, "We are using CRISPR/Cas9 technology to develop new processes to produce enhanced engineered cell therapies to treat serious cancers, such as AML, that traditional methods cannot effectively treatOur proprietary platform provides powerful tools to produce more efficient engineering cellsWe plan to advance NTLA-5001 into clinical trials next year."acute myelotic leukemia (AML) is the most common type of adult leukemia, but can occur at any ageAML is sometimes caused by chemotherapy or radiation therapy for other cancersLeukemia cells can be released into the bloodstream and transported to other organs, and continue to grow and differentiate, forming small lumps (green tumors) in the skin, gums, or eyes
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
